Nearly Half of Kidney Failure Patients Never Start the Transplant Process

Kidney transplantation is the gold standard treatment for end-stage renal disease, offering survival benefits that far outpace long-term dialysis. Yet a major new study from NYU Langone Health and NYU Grossman School of Medicine reveals that the majority of eligible patients never make it through the door.

Researchers examined the transplant referral pipeline among Americans diagnosed with kidney failure. Their central finding is stark: nearly half of those referred for transplantation never initiate the process needed to be considered a candidate. Fewer than one in five patients complete the full evaluation and secure placement on the waitlist.

This cascading attrition across the referral-to-waitlist pathway represents an enormous lost opportunity for life extension. Transplant recipients typically live years to decades longer than matched patients remaining on dialysis. Each patient lost before reaching the waitlist is a preventable reduction in lifespan.

The findings point to multiple potential failure points: inadequate follow-through after initial referral, complex multi-step evaluation requirements, socioeconomic and logistical barriers, and possible disparities in how referrals are communicated and supported. The study does not identify a single cause but frames this as a systemic health-systems problem requiring coordinated intervention.

For clinicians, the implications are immediate. Transplant centers, nephrologists, and primary care providers need better tools to track patients through the referral pipeline and intervene when individuals disengage. For the longevity-minded reader, this research underscores that survival in serious chronic disease is not solely a biological problem — access to care and navigation support are equally determinative. Systemic reforms in transplant evaluation pathways could extend thousands of lives annually without requiring any new medical technology.